Skip to content
OpenCapital
Get started

4D Molecular Therapeutics FDMT Unpaid Costs From ATM Offering Program In Accrued And Other Current Liabilities

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$602.22M+215%
Enterprise value$550.27M+574%
P/S6.8×-8,306×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept fdmt:UnpaidCostsFromATMOfferingProgramInAccruedAndOtherCurrentLiabilities.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's unpaid costs from atm offering program in accrued and other current liabilities.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 4D Molecular Therapeutics's unpaid costs from ATM offering program in accrued and other current liabilities?
4D Molecular Therapeutics (FDMT) reported unpaid costs from ATM offering program in accrued and other current liabilities of $98K in Q1 2026.